

BAB 5

KESIMPULAN & SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian yang telah dilakukan pada 10 jurnal terkait efektivitas dan profil keamanan bedaquiline pada pasien *Multidrug Resistance Tuberculosis* yang dilaksanakan dari bulan januari 2022-maret 2022 dapat disimpulkan bahwa:

1. Penggunaan regimen bedaquiline sebagai salah satu kombinasi OAT pasien *MDR-TBC* efektif berdasarkan durasi kultur konversi, persentase sputum konversi, tingkat mortalitas dan prosentase kesembuhan.
2. Penggunaan bedaquiline sebagai salah satu kombinasi OAT pasien *MDR-TBC* perlu dilakukan monitoring lebih lanjut terutama pada EKG, peningkatan serum hati dan efek samping lainnya yang dapat terjadi pada pasien.

5.2 Saran

1. Perlu dilaksanakan penelitian lebih lanjut terkait kombinasi regimen OAT yang paling efektif serta profil keamanan yang disesuaikan untuk pasien *MDR-TBC*
2. Memperluas database yang digunakan sehingga artikel ilmiah yang digunakan dapat semakin banyak
3. Sebaiknya dilaksanakan meta-analisis untuk melihat signifikansi hasil dari beberapa penelitian dengan karakteristik maupun hasil yang sama agar didapatkan kesimpulan yang lebih objektif mengenai efektivitas dan profil keamanan penggunaan bedaquiline.

DAFTAR PUSTAKA

- Amalia, E., Nindatama, M.R., Hayati, L., Handayani, D., 2015, Identifikasi Mutasi Gen rpoB Ser531Leu Mycobacterium tuberculosis Yang Berhubungan Dengan Resistensi Rifampisin, *Biomedical Journal of Indonesia*, **1(01)**: 30-34
- Bonnet, M., Bastard, M., du Cros, P., Khamraev, A., Kimenye, K., & Khurkhumal, S. et al. (2016). Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. *The International Journal Of Tuberculosis And Lung Disease*, **20(2)**: 177-186.
- Borisov, S., Filippov, A., Ivanushkina, T., Ivanova, D., & Litvinova, N. (2016). *Bedaquiline-containing regimens for MDR TB treatment – focus on the safety. Tuberculosis*.
- Borisov, S., Dheda, K., & Enwerem, M. (2017). Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *European Respiratory Journal*, **49(5)**: 1700387.
- Chahine, E. B., Karaoui, L. R., & Mansour, H. 2013. *Bedaquiline. Annals of Pharmacotherapy*, **48(1)**: 107-115.
- Conradie, F., Diacon, A., Ngubane, N., Howell, P., Everitt, D., & Crook, A. et al. (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *New England Journal Of Medicine*, **382(10)**, 893-902.
- Drugbank^a, 2021, Bedaquiline, Diakses pada tanggal 20 September 2021, <https://go.drugbank.com/drugs/DB08903>
- Gao, M., Gao, J., Xie, L., Wu, G., Chen, W., & Chen, Y. et al. (2021). Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. *Clinical Microbiology And Infection*, **27(4)**: 597-602.
- Grayson, M. L., Cosgrove, S.E., McCarthy, J. S., & Crowe, S., 2018, *Kucer's the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs 7th Edition*. Boca Raton: CRC Press, Taylor & Francis Group.
- Guglielmetti, L., Le Dû, D., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., Fréchet-Jachym, M. 2016. Is Bedaquiline as

- effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. *European Respiratory Journal*, **48(2)**: 582-585.
- Hewison, C., Bastard, M., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., & Avaliani, Z. et al. (2018). *Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia*.
- Hwang, H., Kang, H., Kwon, Y., & Jeon, D. (2021). Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid. *Clinical Infectious Diseases*, **73(8)**: 1362-1369.
- Katzung, B.G., 2018, *Basic & Clinical Pharmacology 14th Edition*, San Francisco, McGrawHill Education.
- Kementerian Kesehatan RI, 2017, *Buku Panduan Penilaian Teknologi Kesehatan Efektivitas dan Evaluasi Ekonomi*, Kementerian Kesehatan RI, Jakarta.
- Kim, C., Kim, T., Shin, H., Ko, Y., Hun Choe, Y., Kim, H., & Kwon, Y. (2018). Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. *European Respiratory Journal*, **51(3)**: 1702467.
- Marzali, A., 2016, Menulis Kajian Literatur, *Jurnal Etnosia*, **1(2)**: 27-36
- Namdar, R., Peloquin, C., 2020, 'Tuberculosis' in DiPiro, Joseph T., Yee, Gary C., Posey, L. M., Haines, S. T., Nolin, T. D., Ellingrod, V. L. (eds), *Pharmacotherapy A Pathophysiologic Approach 11th ed.*, McGraw Hill, New York.
- Okoli, C. and Schabram, K., 2010, A Guide to Conducting a Systematic Literature Review of Information Systems Research, *Sprouts: Working Papers on Information Systems*, **10(26)**: 1-50.
- Pym, A., Diacon, A., Tang, S., Conradie, F., Danilovits, M., & Chuchottaworn, C. et al. (2015). Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. *European Respiratory Journal*, **47(2)**: 564-574.
- Ring, N.A., Ritchie, K., Mandava, L., and Jepson, R., 2011, *A Guide to Synthesising Qualitative Research for Researchers Undertaking Health Technology Assessments and Systematic Reviews*, NHS *Quality Improvement Scotland* (NHS QIS).

- Salhotra, V., Sachdeva, K., Kshirsagar, N., Parmar, M., Ramachandran, R., & Padmapriyadarsini, C. et al. (2020). Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. *Indian Journal Of Tuberculosis*, **67(1)**: 29-37.
- Siregar, M.I.T., 2015, Mekanisme Resistensi Isoniazid & Mutasi Gen KatG Ser315Thr (G944C) Mycobacterium Tuberculosis Sebagai Penyebab Tersering Resistensi Isoniazid, *JMJ*, **3(02)**: 119-131
- Smith, S. E., Pratt, R., Trieu, L., Barry, P. M., Thai, D. T., Ahuja, S. D., & Shah, S. (2017). *Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993–2014*. *Clinical Infectious Diseases*, **65(9)**: 1437–1443.
- Tjekyan, S., Novita, E., Ismail, Z., 2017, Multidrug-Resistant Tuberculosis (MDR-TB): Incidence Rate in Palembang City South Sumatra, Indonesia, *Jurnal Biotek Medisiana Indonesia*, **7(01)**: 1-7
- United States Food and Drug Administration, 2013, FDA Approval for Bedaquiline: Sirturo Medication Guide, *FDA public health advisory*. Washington, DC.
- Van Heeswijk, R. P., Danneman, B., & Hoetelmans, R. M. (2014), Bedaquiline: A Review of Human Pharmacokinetics and Drug-Drug Interactions, *Journal of Antimicrobial Chemotherapy*, **69(9)**: 2310-2318.
- World Health Organization, 2020, *Definitions and reporting framework for tuberculosis 2013 Revision*, Geneva: World Health Organization
- World Health Organization, 2020, *Global Tuberculosis Report 2020*, Geneva: World Health Organization
- World Health Organization, 2020, *The Top Ten Cause of Death*, diakses pada tanggal 9 Oktober 2021 <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
- World Health Organization, 2020, *WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment*, Geneva: World Health Organization
- World Health Organization, 2020, n. *WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis - Rapid Diagnostics for Tuberculosis Detection*, Geneva: World Health Organization.